Russell Investments Group Ltd. Reduces Stock Holdings in Omnicell, Inc. $OMCL

Key Points

• Russell Investments Group Ltd. reduced its stock position in Omnicell, Inc. by 17.7%, ending with approximately 86,462 shares valued at $3,023,000.
• Omnicell reported a net revenue increase of 5.0% year-over-year, with earnings per share of $0.45, which exceeded analysts' estimates of $0.30.
• Research analysts have a consensus rating of "Moderate Buy" for Omnicell, with a price target averaging $46.71 despite recent adjustments from several firms.

Russell Investments Group Ltd. lessened its stake in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 17.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 86,462 shares of the company's stock after selling 18,635 shares during the quarter. Russell Investments Group Ltd. owned approximately 0.18% of Omnicell worth $3,023,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Victory Capital Management Inc. increased its position in Omnicell by 10.1% during the 1st quarter. Victory Capital Management Inc. now owns 1,680,347 shares of the company's stock worth $58,745,000 after purchasing an additional 154,038 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Omnicell by 31.6% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,642,626 shares of the company's stock worth $73,127,000 after buying an additional 394,820 shares during the last quarter. Lazard Asset Management LLC boosted its stake in Omnicell by 81.6% in the 4th quarter. Lazard Asset Management LLC now owns 1,641,817 shares of the company's stock worth $73,093,000 after buying an additional 737,536 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in Omnicell by 4.9% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 1,196,990 shares of the company's stock worth $53,290,000 after buying an additional 56,117 shares during the last quarter. Finally, Toronto Dominion Bank acquired a new stake in Omnicell in the 4th quarter worth about $30,637,000. Hedge funds and other institutional investors own 97.70% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts have issued reports on OMCL shares. Wells Fargo & Company raised their price target on Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research note on Monday, July 21st. Benchmark decreased their price target on Omnicell from $62.00 to $40.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Bank of America raised their price objective on Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a report on Friday, May 23rd. Wall Street Zen downgraded Omnicell from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 9th. Finally, Piper Sandler cut their price objective on Omnicell from $57.00 to $55.00 and set an "overweight" rating on the stock in a report on Monday, August 11th. Four equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Stock Down 2.1%

Shares of NASDAQ:OMCL traded down $0.69 during mid-day trading on Friday, hitting $32.59. 595,171 shares of the company traded hands, compared to its average volume of 577,128. The firm has a market cap of $1.50 billion, a P/E ratio of 65.18, a PEG ratio of 7.12 and a beta of 0.78. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.24 and a current ratio of 1.42. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.74. The firm's 50 day simple moving average is $30.07 and its 200 day simple moving average is $31.56.

Omnicell (NASDAQ:OMCL - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.45 EPS for the quarter, beating the consensus estimate of $0.30 by $0.15. The business had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a return on equity of 4.27% and a net margin of 2.01%.The company's revenue was up 5.0% on a year-over-year basis. During the same period last year, the business posted $0.51 EPS. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. On average, equities analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.